J&J, Boston U partner to map early detection biomarkers for lung cancer

The Johnson & Johnson Innovation LLC unit of Johnson & Johnson (NYSE:JNJ) and Boston University unveiled a five-year collaboration to identify biomarkers for early stage lung cancer. The research includes a precancer genome atlas (PCGA) study, and the partners aim to find new therapeutic targets and develop interceptive products. The partners said

Read the full 523 word article

User Sign In